Cassava Sciences Inc SAVA:NASDAQ

Earnings Announcement Next Earnings date is expected on 11/03/2020
Last Price$8.35Cboe Real-Time Last Sale as of 12:10PM ET 10/30/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.38(4.35%)
Bid (Size)$8.31 (100)
Ask (Size)$8.49 (100)
Day Low / High$8.26 - 8.70
Volume429.8 K
 

View Pharmaceuticals: Other IndustryPeer Comparison as of 10/30/2020

 

Cassava Sciences Inc ( NASDAQ )

Price: $8.35
Change: -0.38 (4.35%)
Volume: 429.8 K
12:10PM ET 10/30/2020
 
 

CTI Biopharma Corp ( NASDAQ )

Price: $3.18
Change: +0.02 (0.63%)
Volume: 137.7 K
11:45AM ET 10/30/2020
 
 

Agile Therapeutics Inc ( NASDAQ )

Price: $2.80
Change: -0.16 (5.41%)
Volume: 370.9 K
12:06PM ET 10/30/2020
 
 

Aclaris Therapeutics Inc ( NASDAQ )

Price: $3.80
Change: -0.03 (0.78%)
Volume: 130.5 K
12:13PM ET 10/30/2020
 
 

AcelRx Pharmaceuticals Inc ( NASDAQ )

Price: $1.73
Change: -0.07 (3.89%)
Volume: 211.5 K
12:19PM ET 10/30/2020
 

Read more news Recent News

--Analyst Actions: Cantor Fitzgerald Starts Cassava Sciences at Overweight With $24 Price Target
7:55AM ET 10/23/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Analyst Actions: HC Wainwright Upgrades Cassava Sciences to Buy From Neutral; Price Target is $20
8:19AM ET 9/23/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Insider Trends: Cassava Sciences Sees 90 Days of Insider Selling, Trend Reduced with Share Purchase
4:03PM ET 9/21/2020 MT Newswires

Sanford Robertson, Director, executed a purchase for 36,281 shares of Cassava Sciences (SAVA) on Sep 18, 2020, for $323,627. After the Form 4 filing with...

Insider Trends: Cassava Sciences Sees Insider Buy Easing 90-Days of Sells
5:18PM ET 9/17/2020 MT Newswires

Sanford Robertson, Director, bought 213,719 shares of Cassava Sciences (SAVA) on Sep 17, 2020, for $1,491,759. Robertson, after the transactions...

Company Profile

Business DescriptionCassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX. View company web site for more details
Address7801 North Capital of Texas Highway
Austin, Texas 78731
Phone+1.512.501.2444
Number of Employees9
Chairman, President & Chief Executive OfficerRemi Barbier
Director, Chief Operating & Medical OfficerNadav Friedmann
Chief Financial OfficerEric J. Schoen
Secretary & Independent DirectorMichael J. O'Donnell

Company Highlights

Price Open$8.78
Previous Close$8.73
52 Week Range$1.21 - 12.68
Market Capitalization$208.1 M
Shares Outstanding24.9 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement11/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.22
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-20.32%

Analyst Ratings as of 10/21/2020

Buy
3
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset